Voyager Therapeutics (VYGR) Profit After Tax (2014 - 2026)

Voyager Therapeutics has reported Profit After Tax for 13 years, with the latest figure at -$295000.0 in Q1 2026.

• Quarterly Profit After Tax fell 241.83% year-over-year to -$295000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (down 220.41% YoY) and the FY2025 annual result came in at -$119.3 million, down 33126.18% from the prior year.
• Profit After Tax rose to -$295000.0 in Q1 2026 per VYGR's latest filing, from -$27.0 million in the prior quarter.
• Over five years, Profit After Tax peaked at $132.5 million in Q4 2023 and troughed at -$33.4 million in Q2 2025.
• A 5-year average of $4.2 million and a median of -$10.1 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax surged 681.85% in 2023, then plunged 7115.78% in 2025.
• Over 5 years, Profit After Tax stood at -$23.7 million in 2022, then surged by 659.03% to $132.5 million in 2023, then sank by 100.28% to -$374000.0 in 2024, then slumped by 7115.78% to -$27.0 million in 2025, then surged by 98.91% to -$295000.0 in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$295000.0, -$27.0 million, and $228000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.